The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot study evaluating the safety, tolerability, and efficacy of doxorubicin and pembrolizumab in patients with metastatic or unresectable soft tissue sarcoma.
 
Michael B. Livingston
No Relationships to Disclose
 
Megan Jagosky
No Relationships to Disclose
 
Myra M. Robinson
No Relationships to Disclose
 
William Ahrens
No Relationships to Disclose
 
Jennifer H Benbow
Patents, Royalties, Other Intellectual Property - Yale University
 
Carol J. Farhangfar
No Relationships to Disclose
 
David Foureau
Research Funding - Celgene; TeneoBio
 
Deirdre Maxwell
No Relationships to Disclose
 
Emily Baldrige
No Relationships to Disclose
 
Nury Steuerwald
No Relationships to Disclose
 
Colin J Anderson
No Relationships to Disclose
 
Joshua Patt
No Relationships to Disclose
 
Jeffrey Kneisl
No Relationships to Disclose
 
Edward S. Kim
Honoraria - AstraZeneca; Boehringer Ingelheim; Merck; Pfizer; Roche/Genentech; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Pfizer; Roche/Genentech; Takeda
Research Funding - Boehringer Ingelheim; Genentech/Roche; Ignyta; Merck
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Genentech/Roche; Merck; Pfizer; Takeda